|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,719.00 GBX | +1.42% |
|
+3.90% | -19.15% |
| 07-17 | WINNERS & LOSERS: Vega ups Vodafone stake; GSK drug trial disappoints | AN |
| 07-16 | British Equities Rise as Economic Rebound Offsets Middle East Tensions | MT |
Company Valuation: Experian plc
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 35,457 | 30,027 | 39,859 | 42,122 | 30,850 | 32,606 | - | - |
| Change | - | -15.31% | 32.75% | 5.68% | -26.76% | 5.69% | - | - |
| Enterprise Value (EV) 1 | 39,374 | 33,924 | 43,813 | 46,770 | 36,084 | 38,110 | 37,361 | 36,408 |
| Change | - | -13.84% | 29.15% | 6.75% | -22.85% | 5.61% | -1.97% | -2.55% |
| P/E | 31.1x | 39.4x | 33.5x | 36.4x | 21x | 20.1x | 17.3x | 15.4x |
| PBR | 9.01x | 7.71x | 8.68x | 8.41x | 5.69x | 6.18x | 5.41x | 4.71x |
| PEG | - | -1.2x | 0.6x | -12.81x | 0.7x | 1.8x | 1.1x | 1.2x |
| Capitalization / Revenue | 5.64x | 4.54x | 5.62x | 5.6x | 3.65x | 3.55x | 3.3x | 3.06x |
| EV / Revenue | 6.26x | 5.13x | 6.17x | 6.22x | 4.27x | 4.14x | 3.78x | 3.42x |
| EV / EBITDA | 18.5x | 14.9x | 17.9x | 17.8x | 12x | 11.5x | 10.4x | 9.33x |
| EV / EBIT | 23.9x | 18.9x | 22.7x | 22.5x | 15.1x | 14.3x | 12.8x | 11.3x |
| EV / FCF | 30x | 31.1x | 39.6x | 34.5x | 23.8x | 20.8x | 19.1x | 17x |
| FCF Yield | 3.33% | 3.21% | 2.53% | 2.9% | 4.19% | 4.8% | 5.23% | 5.9% |
| Dividend per Share 2 | 0.5175 | 0.5475 | 0.585 | 0.625 | 0.6925 | 0.7679 | 0.863 | 0.957 |
| Rate of return | 1.33% | 1.66% | 1.34% | 1.36% | 2.02% | 2.1% | 2.36% | 2.62% |
| EPS 2 | 1.248 | 0.836 | 1.302 | 1.265 | 1.634 | 1.82 | 2.112 | 2.382 |
| Distribution rate | 41.5% | 65.5% | 44.9% | 49.4% | 42.4% | 42.2% | 40.9% | 40.2% |
| Net sales 1 | 6,288 | 6,619 | 7,097 | 7,523 | 8,445 | 9,194 | 9,895 | 10,642 |
| EBITDA 1 | 2,129 | 2,276 | 2,449 | 2,630 | 3,010 | 3,313 | 3,607 | 3,902 |
| EBIT 1 | 1,645 | 1,794 | 1,928 | 2,083 | 2,397 | 2,668 | 2,930 | 3,215 |
| Net income 1 | 1,165 | 770 | 1,199 | 1,166 | 1,502 | 1,606 | 1,836 | 2,055 |
| Net Debt 1 | 3,917 | 3,897 | 3,954 | 4,648 | 5,234 | 5,504 | 4,755 | 3,802 |
| Reference price 2 | 38.79 | 32.91 | 43.66 | 46.10 | 34.31 | 36.58 | 36.58 | 36.58 |
| Nbr of stocks (in thousands) | 914,038 | 912,453 | 912,895 | 913,734 | 899,266 | 891,366 | - | - |
| Announcement Date | 5/18/22 | 5/17/23 | 5/15/24 | 5/14/25 | 5/20/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 20.1x | 4.14x | 11.5x | 2.1% | 32.61B | |
| 16.62x | 2.87x | 9.33x | 1.17% | 6.56B | |
| 12.3x | - | - | - | 1.25B | |
| 29.31x | 2.64x | 10.32x | - | 372M | |
| Average | 19.58x | 3.22x | 10.38x | 1.64% | 10.2B | |
| Weighted average by Cap. | 19.39x | 3.92x | 11.13x | 1.94% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- EXPN Stock
- Valuation Experian plc
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
